AI Pathology Test Outperforms Oncotype DX Gold Standard in HR+/HER2- Patients
kjgeras · x · 2026-07-06
In HR+/HER2- patients (n=858), this AI pathology test was directly compared against the 20-year clinical gold standard Oncotype DX (21-gene assay). It achieved a C-index of 0.67 vs. 0.61 and outperformed Oncotype DX across multiple thresholds in decision curve analysis.
More from Research
- rauchg reproduces OpenAI's covert CPU-channel finding: chat across Firecracker microVMs with no network — ccerrato147 · 2026-10-27
- Microsoft Research: ForkPilot cuts long-horizon agent compute by up to 59% — EliasEskin · 2026-10-27
- Microsoft's TeleTune evolves agent skills from offline user telemetry — EliasEskin · 2026-10-27
- FlexGlue: sparse-to-dense matching that beats dense accuracy at a fraction of the cost — zhenjun_zhao · 2026-10-27
- Mundo turns a few room photos into an explorable, simulatable 3D world — at 1.5 FPS — mark_k · 2026-10-27
- Mathematics as an experimental science: Marc Lelarge to talk LLM-driven math experiments at ENS — marc_lelarge · 2026-10-27